1-((2-oxo-1-pyrrolidynyl)acetyl)piperazine | 113933-08-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-((2-oxo-1-pyrrolidynyl)acetyl)piperazine
• 英文别名: [(2-oxopyrrolidinyl-1-yl)acetyl]piperazine；(2-Oxopyrrolidin-1-yl)acetylpiperazine；1-(2-oxo-2-piperazin-1-ylethyl)pyrrolidin-2-one
• CAS: 113933-08-7
• 化学式: C₁₀H₁₇N₃O₂
• 分子量: 211.264
• InChiKey: YFXAZRCWZHAOHD-UHFFFAOYSA-N

物化性质

• 熔点：
  116-117 °C(Solv: isopropanol (67-63-0); ethyl ether (60-29-7))
• 沸点：
  450.5±40.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-((2-oxo-1-pyrrolidynyl)acetyl)piperazine 生成 Phenyl 4-[2-(2-oxopyrrolidin-1-yl)acetyl]piperazine-1-carboxylate
  参考文献：
  名称：

  MATSUMURA, XIROSI;XASIDZUMEH, XIROSI;MATSUSITA, TAKA;NAGANARI, MASAESI

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氧代-1-吡咯烷乙酸甲酯 、 哌嗪 以69%的产率得到
  参考文献：
  名称：

  MATSUMURA, XIROSI;XASIDZUMEH, XIROSI;MATSUSITA, TAKA;NAGANARI, MASAESI

  摘要：

  DOI：

文献信息

• ALICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1970373A1

  公开（公告）日：2008-09-17

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下是该公式表示的脂环杂环化合物或其药用可接受盐： 其中环A是杂环，环B是碳环，杂环等，P1和P2是CH或N，q和r为0至2，X为-NH-，-O-，-CH2-等，Y为- -，-CO-，-SO2-等，Z为-CO-，-SO2-等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基， 可用作CCR4功能的控制剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• N-(2-oxpyrrolidin-1-yl-)acetyl)piperazine derivatives and drug for
  申请人：Shionogi & Co., Ltd.

  公开号：US04904663A1

  公开（公告）日：1990-02-27

  A compound of the formula: ##STR1## (wherein R is --SO.sub.2 R.sup.1 or --CONHR.sup.2 ; R.sup.1 is C.sub.1 -C.sub.5 alkyl, C.sub.8 -C.sub.12 phenylalkenyl, amino, dimethylamino, optionally substituted C.sub.8 -C.sub.12 aryl, or 5- or 6-membered heterocyclic group including at least one hetero atom selected from the group consisting of N, S, and O; R.sup.2 is amino, C.sub.1 -C.sub.8 alkylamino, C.sub.1 -C.sub.8 alkyl, or optionally substituted C.sub.8 -C.sub.12 aryl) or its pharmaceutically acceptable acid-addition salt, being useful as a drug for senile dementia, psychotropic, or antiamnesia agent is provided through several routes.

  该化合物的结构式为：##STR1##（其中R为--SO.sub.2 R.sup.1或--CONHR.sup.2；R.sup.1为C.sub.1-C.sub.5烷基，C.sub.8-C.sub.12苯基烯基，氨基，二甲胺基，可选择取代的C.sub.8-C.sub.12芳基，或包含至少一种异原子（选自N、S和O）的5-或6元杂环基；R.sup.2为氨基，C.sub.1-C.sub.8烷基氨基，C.sub.1-C.sub.8烷基，或可选择取代的C.sub.8-C.sub.12芳基）或其药用可接受的酸盐，可用作治疗老年性痴呆症、精神药物或抗遗忘剂的药物，通过多种途径提供。
• Alicyclic Heterocyclic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182140A1

  公开（公告）日：2009-07-16

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P 1 and P 2 are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is —CO—, —SO 2 —, etc., and R 3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR 4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下式子所示的脂环杂环化合物或其药学上可接受的盐： 其中环A为杂环，环B为碳环，杂环等，P1和P2为CH或N，q和r为0至2，X为—NH—，—O—，—CH2—等，Y为— —，—CO—，—SO2—等，Z为—CO—，—SO2—等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基，用作CCR4功能调节剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• New N-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
  申请人：PRODES S.A.

  公开号：EP0089900A1

  公开（公告）日：1983-09-28

  The present invention concerns new N-[(2-oxo-1-pyrrolidinyl)acetyl] piperazines of the following formula: wherein R represents hydrogen or an alkyl group which contains 1 to 3 carbon atoms which can be arranged as straight or branched chain and R' represents an allyl, cinnamyl or p-methoxybenzyl group, as well as their pharmaceutically acceptable acid addition salts. These piperazine derivatives are useful as drugs, especially in the treatment of cerebrovascular disturbances in the elderly.

  本发明涉及下式的新型 N-[(2-氧代-1-吡咯烷基)乙酰基]哌嗪： 其中 R 代表氢或含有 1 至 3 个碳原子的烷基，可以是直链或支链，以及 R'代表烯丙基、肉桂基或对甲氧基苄基、 以及它们的药学上可接受的酸加成盐。 这些哌嗪衍生物可用作药物，特别是治疗老年人的脑血管疾病。
• N-[(2-Oxopyrrolidin-1-yl)-acetyl]piperazine derivatives and drug for senile dementia
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0299493A2

  公开（公告）日：1989-01-18

  A compound of the formula: (wherein R is -SO₂R¹ or -CONHR²; R¹ is C₁-C₅ alkyl, C₈-C₁₂ phenyl­alkenyl, amino, dimethylamino, optionally substituted C₆-C₁₂ aryl, or 5- or 6-membered heterocyclic group including at least one hetero atom selected from the group consisting of N, S, and O; R² is amino, C₁-C₅ alkylamino, C₁-C₅ alkyl, or optionally substituted C₆-C₁₂ aryl) or its pharmaceutically acceptable acid-addition salt, being useful as a drug for senile dementia, psychotropic, or antiamnesia agent is provided through several routes.

  式中的化合物： (其中 R 是 -SO₂R¹ 或 -CONHR²；R¹ 是 C₁-C₅烷基、C₈-C₁₂苯基烯基、氨基、二甲基氨基、任选取代的 C₆-C₁₂芳基或包括至少一个选自 N、S 和 O 组成的组的杂原子的 5 或 6 元杂环基团；R² 是氨基、C₁-C₅ 烷基氨基、C₁-C₅ 烷基或任选取代的 C₆-C₁₂ 芳基）。 或其药学上可接受的酸加成盐，可通过多种途径用作老年痴呆症药物、精神药物或抗失眠药物。